Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 multi-regional open-label ascending dose study of KK8005 in adults with X-linked hypophosphatemia
jRCT2031260424Phase 2Not yet recruiting
- Sponsor
- Kyowa Kirin
- Start
- Sep 2026
01
Overview
Phase 2, open-label, single-arm trial of KK8005 in X-linked hypophosphataemia (XLH), sponsored by Kyowa Kirin. Primary endpoint: Number of participants with adverse events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
KK8005
03
Conditions
X-linked hypophosphataemia (XLH)
Beyond the preview
Go deeper on jRCT2031260424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260424.